Boston Scientific (NYSE:BSX) Issues Q2 2025 Earnings Guidance

Boston Scientific (NYSE:BSX - Get Free Report) issued an update on its second quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.710-0.730 for the period, compared to the consensus estimate of 0.710. The company issued revenue guidance of $4.8 billion-$4.9 billion, compared to the consensus revenue estimate of $4.9 billion. Boston Scientific also updated its FY 2025 guidance to 2.870-2.940 EPS.

Boston Scientific Stock Performance

Boston Scientific stock traded up $1.19 during midday trading on Friday, hitting $99.75. The stock had a trading volume of 6,325,460 shares, compared to its average volume of 6,537,560. Boston Scientific has a 52-week low of $71.88 and a 52-week high of $107.17. The company has a market capitalization of $147.58 billion, a PE ratio of 79.78, a P/E/G ratio of 2.79 and a beta of 0.68. The firm's fifty day moving average is $100.84 and its two-hundred day moving average is $98.62. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The company's revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.56 earnings per share. On average, research analysts forecast that Boston Scientific will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Barclays boosted their price objective on Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Royal Bank of Canada lifted their target price on Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Robert W. Baird upped their price target on Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. BTIG Research reaffirmed a "buy" rating and set a $124.00 price objective on shares of Boston Scientific in a report on Wednesday, April 23rd. Finally, Morgan Stanley lifted their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. Twenty-one analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $116.00.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 56,372 shares of the firm's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total value of $5,799,551.36. Following the completion of the sale, the executive vice president now directly owns 178,342 shares in the company, valued at $18,347,824.96. This trade represents a 24.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the transaction, the senior vice president now owns 36,193 shares in the company, valued at $3,441,592.37. This trade represents a 11.77% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 411,970 shares of company stock worth $42,406,693. Corporate insiders own 0.50% of the company's stock.

Institutional Trading of Boston Scientific

A hedge fund recently raised its stake in Boston Scientific stock. Brighton Jones LLC increased its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 0.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 27,376 shares of the medical equipment provider's stock after acquiring an additional 226 shares during the period. Brighton Jones LLC's holdings in Boston Scientific were worth $2,445,000 at the end of the most recent quarter. Institutional investors own 89.07% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.